GlassScriptPhysician profile
Abdul Baqi
NPI 1538780440
$4,293.43
in general payments reported to CMS, 2019-2025
22 companies · $3,294 in 2025
The $3,294 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.96 · 2023: $443 · 2024: $541 · 2025: $3,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,021 · Travel and Lodging: $1,923 · Education: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.89 |
| Travel and Lodging | $1,922.77 |
| Education | $333.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cordis US Corp. | $1,322.05 | 2025 | Angioguard, Precise Pro Rx, Mynx Control Venous |
| Philips North America LLC | $889.47 | 2025 | Coronary Other, Coronary Undivided |
| Abbott Laboratories | $303.74 | 2023-2025 | Perclose Prostyle, Ensite |
| Atricure, INC. | $285.48 | 2024-2025 | Synergy Ablation System, Atriclip Laa Exclusion System |
| Medtronic, INC. | $237.57 | 2023 | Onyx Frontier |
| Scpharmaceuticals INC. | $125.71 | 2025 | |
| Amgen INC. | $115.20 | 2025 | Repatha |
| Novo Nordisk INC | $110.01 | 2022-2024 | |
| Shockwave Medical, INC | $101.87 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Actelion Pharmaceuticals US, INC. | $99.16 | 2025 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $97.04 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bayer Healthcare Pharmaceuticals INC. | $86.53 | 2025 | |
| Cleerly, INC. | $84.78 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Abiomed | $81.73 | 2024-2025 | Impella |
| Bridgebio Pharma, INC. | $76.48 | 2025 | Attruby |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $74.57 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $67.28 | 2023 | Verquvo |
| Boston Scientific Corporation | $32.65 | 2025 | Watchman Flx |
| Terumo Medical Corporation | $32.17 | 2025 | Angio-Seal, Optitorque, Glidesheath Slender |
| Kiniksa Pharmaceuticals International, Plc | $31.87 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $22.87 | 2023 | Camzyos |
| Novartis Pharmaceuticals Corporation | $15.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Baqi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.